Carisma Enters into a Research Collaboration with Phio Pharmaceuticals
September 9, 2019
“Metastatic solid tumors have been an intractable challenge for engineered cell therapies. Our platform technology, based on the genetically engineered macrophage, has a unique opportunity to provide benefit in this disease state,” said Dr. Michael Klichinsky, co-Founder and Vice President of Discovery at Carisma. “We are excited to work with Phio to evaluate sd-rxRNA mediated silencing of genes that have the potential to enhance macrophage immunotherapy.” For full press release, click here.